Navigation Links
UCSD research team identifies novel anticancer drug from the sea
Date:2/11/2008

A collaborative team of researchers spearheaded by Dennis Carson M.D., professor of medicine and director of the Rebecca and John Moores UCSD Cancer Center at the University of California, San Diego (UCSD) has identified a potent new anti-cancer drug isolated from a toxic blue-green algae found in the South Pacific. The properties of somocystinamide A (ScA) are described in a paper that will be published online in Proceedings of the National Academy of Science the week of February 11 -15.

We are excited because we have discovered a structurally unique and highly potent cancer-fighting compound, said Dwayne G. Stupack, associate professor of pathology at the Moores UCSD Cancer Center. We envision it will be perfect for emerging technology, particularly nanotechnology, which is being developed to target cancerous tumors without toxic side effects.

The ScA compound was found in the cyanobacteria L. Majuscula, also known as mermaids hair, gathered off the coast of Fiji in the South Pacific by the laboratory of William Gerwick at Scripps Institution of Oceanography. A diverse team of researchers from UCSDs Cancer Center, School of Medicine, Skaggs School of Pharmacy and Pharmaceutical Sciences, and Scripps worked to identify, screen and test marine compounds in vitro and in vivo. They found that ScA inhibits neovascularization, the formation of blood vessels that feed tumors, and also had a direct impact on tumor cell proliferation.

The compound isnt toxic to the cyanobacteria itself, but activates a death pathway, present in our cells, said Stupack. When the cells of the blood vessels that feed tumors become activated and proliferate, they become especially sensitive to this agent.

Gerwick noted that if a normal-sized swimming pool full of cancer cells were treated with ScA, it would take only three milligrams about the weight of a grain of rice to kill all of the cancer cells.

Wolf Wrasidlo, Ph.D., senior project scientist at the Moores UCSD Cancer Center and first author of the work, added that the unique structure of this compound lends itself very well to nanotechnology, because it incorporates spontaneously into molecule-sized nanoparticles, important for the kind of highly targeted, combination therapy being developed to treat cancer. The structure is also simple enough that the scientists can reproduce it.

ScA is the first, and most potent compound weve identified so far, Stupack said, adding that it wont be the last, as the Scripps team has identified more than 250 unique compounds from L. Majuscula alone. But we dont yet know how abundant ScA is, or if its feasible to harvest, so it is important that we have been able to produce this natural product in the lab.


'/>"/>

Contact: Debra Kain
ddkain@ucsd.edu
619-543-6163
University of California - San Diego
Source:Eurekalert  

Related medicine news :

1. NeoStrata Research Validates Anti-Aging Benefits of At-Home AHA Peels As Complement to In-Office Non-Invasive Cosmetic Procedures
2. Oregon researchers discover a mechanism leading to cleft palate
3. Penn childhood obesity researchers panelists at AAAS Town Hall Event
4. Researchers at Pulmonary Associates to study airway bypass procedure for severe emphysema
5. Psoriasis Cure Now Applauds Record Government Psoriasis Research Funding
6. Amscot Financial Contributes to the Juvenile Diabetes Research Foundation, Supporting Upcoming Walk for a Cure
7. ECNP launches research grant for young scientists
8. European blood researchers receive award to pursue research opportunities in US
9. P\S\L Group appoints Paul Barnes as Group President P\S\L Research
10. Worlds best analysts compete to win Edelman Prize in operations research and analytics
11. Thousands of Womens Basketball Referees to Wear Pink Whistles February 8-17; Calling For a Cure Program to Raise Funds for Cancer Research
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
UCSD research team identifies novel anticancer drug from the sea
(Date:12/9/2016)... (PRWEB) , ... December 09, 2016 , ... ... whiteboard display solutions, proudly announced today that a new solution for Emergency Departments ... fit in the tight space in Emergency Department examination rooms, and with a ...
(Date:12/8/2016)... Cambridge, MA (PRWEB) , ... December 08, 2016 ... ... the Workers Compensation Research Institute (WCRI) officially opened registration today for its ... Place Hotel in Boston, MA . , The theme of the conference is ...
(Date:12/8/2016)... ... December 08, 2016 , ... CURE Media Group, the nation’s leading digital ... aligned with Upstage Lung Cancer in efforts to combat lung cancer, announced CURE Media ... Jr said, “CURE Media Group is honored to team up with Upstage Lung Cancer ...
(Date:12/8/2016)... (PRWEB) , ... December 08, ... ... Presence Suite 10.2 version gives development continuity to its innovative Unified Instance ... channels management capacity. In addition, this new version optimizes the unattended auto-dialing ...
(Date:12/8/2016)... ... December 08, 2016 , ... Today’s patients are encouraged ... in mind, SIGVARIS has created a new line of anti-embolism stockings to help ... provide the benefits of graduated compression when transitioning from recovery to early rehabilitation. ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... 8, 2016 KEY FINDINGS ... of the market in 2016 and is expected to ... attributed to a large number of surgical procedures that ... largest share in the patient temperature management market.) Patient ... reducing loss of blood during surgeries, lowering the risks ...
(Date:12/8/2016)... Research and Markets has announced the addition ... Adhesion Type, Application, Usability - Forecast to 2025" report to ... , , ... poised to grow at a CAGR of around 3.2% from 2015 ... witnessing include advancements in extracellular microelectrode arrays and intracellular microelectrodes, research ...
(Date:12/8/2016)... 2016  Valeant Pharmaceuticals International, Inc. (NYSE: ... announced positive results from a Phase 3, multicenter ... safety and efficacy of IDP-118 (halobetasol propionate and ... Within the Phase 3 study ... psoriasis, IDP-118 showed statistical significance to vehicle with ...
Breaking Medicine Technology: